ApoA-I Data Presented at European Society of Cardiology Congress

    Multiple presentations included Resverlogix data

    TSX Exchange Symbol: RVX

    CALGARY, Sept. 2 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) is pleased to announce that Dr. Norman Wong presented key
clinical data pertaining to its lead compound, RVX-208, at the European
Society Cardiology (ESC) 2008 Congress in Munich. The presentation titled
"RVX-208 a novel small molecule that increases apolipoprotein A-I enters into
human clinical trials" was delivered on August 31, 2008. In addition to this
presentation, other important data relating to RVX-208 from Resverlogix's
extensive data portfolio was presented by Dr. Jacques Genest of McGill
University and Dr. Stephen Nicholls of the Cleveland Clinic, at the same
    "Over the past year, the scientific community has pushed to the forefront
the importance of a small molecule in the form of an oral tablet that
significantly increases ApoA-I production, HDL functionality and thereby
treats atherosclerosis cardiovascular disease," stated Dr. Jan Johansson,
Senior Vice President Medical Affairs Resverlogix. Johansson further added,
"The ESC is a well regarded scientific meeting as well as one of the largest
with an estimated 25,000 participants. We are pleased to have presented our
data to this esteemed audience."
    Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the body's natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e. transport of
peripheral cholesterol including that of the vessel wall to the liver for
elimination from the body. In multiple human and animal studies
over-expression or repeated infusion of ApoA-I inhibit progression and induce
regression of atherosclerosis in animals and humans.
    RVX-208, a novel small molecule drug that facilitates endogenous ApoA-I
production, is positioned as an emerging drug that holds the most promise for
the treatment of atherosclerosis. RVX-208 is designed to increase ApoA-I
production and thereby raise HDL levels thus enhancing HDL functionality to
augment reverse cholesterol transport.

    About Resverlogix Corp.

    Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.

    This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.

    %SEDAR: 00019253E

For further information:

For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com;
Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: (403)
254-9252, Email: Sarah@resverlogix.com, Website: www.resverlogix.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890